Veru, Inc. (VERU) Reaches Agreement with FDA on Confirmatory Phase 3 Clinical Trial for Sabizabulin
Go back to Veru, Inc. (VERU) Reaches Agreement with FDA on Confirmatory Phase 3 Clinical Trial for Sabizabulin| (NASDAQ: VERU) | Delayed: 2.83 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.83 | 52 Week High | $ | |||
| Open | $2.83 | 52 Week Low | $ | |||
| Day High | $2.83 | P/E | N/A | |||
| Day Low | $2.83 | EPS | $ | |||
| Volume | 1,060 | |||||
